Midissia Therapeutics to Develop Immune Intensification Technology at Immunomic Labs
Last night, Immunomic Therapeutics announced the winner of their Cancer Discovery Incubator Award: Midissia Therapeutics (Midissia). Midissia is a clinical stage immunotherapy start-up focused on immune intensification. The announcement was made at the BioHealth Capital Region Forum, held at MedImmune’s headquarters in Gaithersburg, Maryland.
Midissia Therapeutics is developing personalized dendritic cancer vaccines that have the potential to significantly impact the overarching problems of toxicity, drug resistance and recurrence that plague current modalities of cancer treatment.
Midissia is currently based in San Francisco and incorporated in Delaware. As winner of the Immunomic Therapeutics’ Cancer Discovery incubator, Midissia will conduct work their proof-of-concept experiment in the Immunomic laboratories in Rockville, MD. Additionally, Midissia will receive funding, lab equipment and a unique mentorship with the Immunomic executive team for one year.
“A number of extremely impressive companies applied for our incubator opportunity. The Midissia technology was chosen because it addresses a specific area of need in cancer treatment and the technology and entrepreneur wowed our selection committee,” said Bill Hearl, CEO of Immunomic. “We are thrilled to provide Midissia with a place to grow here in Maryland and look forward to watching their technology advance and benefit future patients.”